Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemangioma 6 Hemangioma, Capillary 4 Multiple Myeloma 2 Fallopian Tube Neoplasms 2 Breast Neoplasms 2 Tuberous Sclerosis 1 Prostatic Neoplasms 1 Neuroblastoma 1 Melanoma 1 Hemangiosarcoma 1 Hemangioma, Cavernous, Central Nervous System 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 56 Etoposide 40 Filgrastim 37 Carboplatin 34 Vincristine 30 Doxorubicin 30 Melphalan 27 Topotecan 25 Isotretinoin 24 Peripheral Blood Stem Cell Transplantation 23 Granulocyte Colony-Stimulating Factor 22 Cisplatin 21 Irinotecan 20 sargramostim 18 Temozolomide 17 humanized 3F8 anti-GD2 monoclonal antibody 15 Radiotherapy 15 3-Iodobenzylguanidine 13 Granulocyte-Macrophage Colony-Stimulating Factor 11 Busulfan 11 dinutuximab 10 Interleukin-2 9 aldesleukin 8 Thiotepa 8 Ifosfamide 8 etoposide phosphate 7 Mesna 7 Vorinostat 6 Stem Cell Transplantation 6 Polymerase Chain Reaction 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neuroblastoma × Propranolol × Clear all

NCT02641314 2024-05-10

METRO-NB2012

University of Cologne

Phase 2 Completed

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡